Tuesday, April 26, 2011 4:14:20 PM
I think no one has ever looked but there are other GPR109A agonists with little or no meaningful lipid-altering effects, so not sure this is due to lower affinity or maybe it's not the only MOA of niacin's effect on lipids. probably both. I would think that investigating this point is important for patients with severe psoriasis as they are at increased risk of cardiovascular mortality. Are you going to take this suggestion to ABT/BIIB or shall I?
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
